Novo Nordisk A/S $NVO Shares Sold by Marietta Investment Partners LLC

Marietta Investment Partners LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 16.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 82,999 shares of the company’s stock after selling 16,311 shares during the quarter. Marietta Investment Partners LLC’s holdings in Novo Nordisk A/S were worth $4,223,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Godfrey Financial Associates Inc. acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $25,000. WealthCollab LLC lifted its holdings in shares of Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after buying an additional 260 shares during the period. American National Bank & Trust acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $28,000. Maseco LLP acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $29,000. Finally, Jackson Grant Investment Advisers Inc. acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk launched the Wegovy pill in the UAE, marking its first market outside the U.S. and signaling the start of a broader international rollout for its obesity franchise. Reuters article
• Positive Sentiment: Novi Health announced a partnership with Novo Nordisk to expand structured weight-care support in Singapore, which could help improve patient access and treatment adoption in another growth market. Yahoo Finance article
• Positive Sentiment: Danske Bank raised Denmark’s GDP forecast to 3.7%, citing export strength supported by demand for Novo Nordisk products, underscoring the company’s importance to the Danish economy. Financial Post article
• Neutral Sentiment: Commentary suggested there may be “light at the end of the tunnel” for Novo Nordisk, but it was opinion-based rather than a new fundamental update. Motley Fool article
• Negative Sentiment: Eli Lilly won back CVS Health, reversing part of Novo Nordisk’s advantage in GLP-1 access and highlighting intensifying competition in the obesity drug market. MarketBeat article
• Negative Sentiment: ASML’s surge to record valuation drew attention to Novo Nordisk’s prior peak as Europe’s most valuable stock, reinforcing how far NVO has fallen from its high-water mark. Yahoo Finance article

Analysts Set New Price Targets

A number of equities analysts recently weighed in on NVO shares. TD Cowen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target for the company. in a report on Tuesday, March 10th. Nordea Equity Research cut Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Wall Street Zen raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Sanford C. Bernstein started coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price target for the company. Finally, Kepler Capital Markets cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $42.06 on Thursday. The stock has a market capitalization of $187.78 billion, a price-to-earnings ratio of 9.87, a PEG ratio of 3.83 and a beta of 0.78. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The stock has a 50-day moving average of $41.35 and a 200 day moving average of $46.24.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion during the quarter. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.46 EPS for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.